Jevtana's Toxicity Profile Makes It a Good Option in Metastatic Prostate Cancer

Article

When other therapies have failed, patients with metastatic prostate cancer who were treated with Jevtana (cabazitaxel) in the third-line setting experienced a toxicity profile similar to that of androgen-targeted therapies, making the chemotherapy agent a valid choice for some patients, according to results from the CARD trial.

When other therapies have failed, patients with metastatic prostate cancer who were treated with Jevtana (cabazitaxel) in the third-line setting experienced a toxicity profile similar to that of androgen-targeted therapies, making the chemotherapy agent a valid choice for some patients, according to results from the CARD trial.

At the European Society of Medical Oncology (ESMO) Congress 2019, CURE spoke with Dr. Arash Rezazadeh Kalebasty, a medical oncologist at Norton Cancer Institute, about the results of the trial and what Jevtana offers patients with metastatic castration-resistant prostate cancer.

Transcript:

One important outcome was the grade 3 and higher toxicities were not really very much higher than in the androgen-targeted therapy arm. I think this is very encouraging because in this population, toxicity matters. A lot of patients are elderly.

The specifics for this trial did exclude patients who were not a good candidate for chemotherapy anyway, but we have to be careful about the benefit versus risk when we offer patients chemotherapy as well.

Related Videos
Image of Dr. Jorge Cortes; a man with short dark hair wearing a suit.
Image of a man with brown hair.
Image of a woman with short brown hair and glasses.
Image of a woman with short brown hair and glasses.
Image of a man with brown hair and a suit and tie.
Image of a woman with brown bobbed hair with glasses.
Image of Dr. Minesh Mehta at ASCO 2024.
Image of a woman with blond hai
Image of a man with rectangular glasses and short dark hair.
Related Content